The BBC is facing questions over transparency after allowing obesity specialists to discuss new weight-loss drugs on air without disclosing their financial ties to pharmaceutical companies. This oversight violates the BBC's own editorial guidelines, though the corporation admitted it 'fell short' in this instance. Critics argue that the lack of disclosure risks undermining public trust, especially as these 'skinny jabs' are under intense scrutiny and debate. The article details specific payments received by the featured experts from drug manufacturers.

Source: GB News